NephCure Kidney International Rings Opening Bell at NYSE August 14, 2014 by Lauren Eva NephCure Kidney International (NKI) rang the opening bell at the New York Stock Exchange (NYSE) at 9:30 AM Friday, August 15, 2014. “We are thrilled to have been asked and for the opportunity to join the legions who have come before us in having this honor,” said Mark Stone, NephCure Kidney International CEO. Representatives from NKI took the podium alongside NephCure Board Members and NephCure families including The Silvermans, The Genatt’s, Michael Levine, and Tim Brink. Five-year-old Jed Silverman had the honor of ringing the bell. “This is an incredible opportunity for NephCure Kidney International. We appreciate the chance to raise awareness of the foundation, and its work to find a cure for the devastating kidney disease FSGS and the other diseases that cause Nephrotic Syndrome,” said Michael Levine, NKI Board Member. Mr. Levine’s 11-year-old son Matthew is currently battling FSGS (Focal Segmental Glomerulosclerosis). More than 8,000 people are diagnosed with Nephrotic Syndrome every year, and FSGS is the leading cause of kidney failure in children. In the United States alone more than 26 million suffer from some form of kidney disease. Since its inception, NephCure has contributed more than $13 million dollars toward FSGS and NS research. NKI remains the only organization dedicated to funding research to end FSGS and NS.
The NephCure Foundation is Now NephCure Kidney International August 14, 2014 by Lauren Eva The NephCure Foundation is Now NephCure Kidney International New Name, Same Dedication to a Cure for FSGS and the diseases that cause Nephrotic Syndrome “We are here to create help for today and hope for tomorrow for thousands of Nephrotic Syndrome and FSGS. It is our mission to accelerate research toward better treatments and a cure for these diseases. We will advance this mission as NephCure Kidney International , a catalyzer, convener, and collaborator of and with the best research minds in glomerular disease, as we look to a future without suffering from these diseases,” said NephCure Kidney International (NKI) CEO Mark Stone. NKI continues to be the sole organization focused on funding research and finding a cure for Focal Segmental Glomerulosclerosis (FSGS) and the diseases that cause Nephrotic Syndrome (NS). Each year, more than 8,000 people are diagnosed with NS, and in the US alone more than 26 million Americans suffer from some form of kidney disease. “Our dedication and commitment to helping patients through accelerating research is as firm as ever, and we trust this commitment is reflected in our new name,” said Marilyn Hailperin, NKI Director of Research. Since its inception, NephCure has contributed more than $13 million dollars toward FSGS and NS research. Look for NephCure’s new brand rollout 9:30 Friday, August 15, 2014 when NKI rings the opening bell at the New York Stock Exchange. Learn more about NKI at www.NephCure.org.
Are You Newly Diagnosed or New to NephCure? August 14, 2014 by Lauren Eva Are you or a family member/friend impacted by Nephrotic Syndrome, FSGS -Focal Segmental Glomerulosclerosis – or MCD – Minimal Change Disease? You have come to the right place! Hearing a foreign diagnosis that is difficult to pronounce, let alone understand, is very unsettling. Know that you are not alone. NephCure Kidney International and our community of patients, patient families, medical professionals, and researchers are here to provide you with the tools you need to get connected, get educated and find out about the latest research and treatment options available. How do I get started? Help us help you, by telling us what brought you here to NephCure Kidney International and what resources you are seeking. It’s easy, just click here, answer a few simple questions. This gives us the jumping off point to find out where you are in your individual journey with Nephrotic Syndrome and how we can provide you with the tools you need to join in the fight for improved treatments and the cure!